<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985046</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai14</org_study_id>
    <nct_id>NCT03985046</nct_id>
  </id_info>
  <brief_title>Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC</brief_title>
  <official_title>A Pilot Study of Sintilimab Plus Chemotherapy Followed by Definitive Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab
      plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced
      esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate</measure>
    <time_frame>up to 42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab plus Chemotherapy</intervention_name>
    <description>Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=6. Once every 3 weeks.</description>
    <arm_group_label>Sintilimab plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Aged 18-75 years

          3. Histologically confirmed esophageal squamous cell carcinoma

          4. Clinical stages T3-4N0M0 or TxN1M0 or TxNxM1a or TxNxM1b (Only for cervical lymph
             nodes or celiac lymph nodes metastasis) based on the 6th UICC-TNM classification

        7. Eastern Cooperative Oncology Group(ECOG) performance status: 0-1 8. Life expectancy ≥3
        months 9. Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×109⁄L; Hemoglobin
        (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×109⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN);
        Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine
        ≤1.5 ULN

        Exclusion Criteria:

          1. Esophageal perforation or hematemesis

          2. Any active autoimmune disease or a history of autoimmune disease (such as the
             following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis,
             enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism and
             hypothyroidism (effective hormone replacement therapy excepted)) and immunosuppressive
             agents or systemic hormonal therapy indicated within 28 days (for adverse events of
             chemoradiotherapy excepted).

          3. Previously received or receiving other PD-1 antibody therapy or other immunotherapy
             against PD-1/PD-L1.

          4. Allergic to macromolecular protein preparations, or to any of the ingredients in
             sintilimab for injection.

          5. Uncontrolled heart diseases or clinical symptoms, such as: (1) New York Heart
             Association(NYHA) class II or higher heart failure; (2) unstable angina; (3)
             myocardial infarction within 1 year; (4)clinically significant arrhythmia requiring
             clinical intervention.

          6. Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B
             (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and
             HCV-RNA is higher than the detection limit of the analytical method); active
             tuberculosis.

          7. Active infection or unexplained fever &gt;38.5 °C within 2 weeks before randomization
             (fever due to tumor excepted, according to investigator).

          8. Patients with fertility reluctant to take contraceptive measures during the trial, or
             female patients pregnant or breastfeeding.

          9. According to the investigator, other factors that may cause termination of the study.
             ie, other serious diseases (including mental illness) require combined treatment,
             family or social factors, which may affect the safety or the collection of trial data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kuaile Zhao, MD</last_name>
    <phone>86-21-64175590</phone>
    <email>kuaile_z@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuaile Zhao, MD.</last_name>
      <phone>+8618017312534</phone>
      <email>kuaile_z@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

